Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | SIGLEC9 | Q9Y336 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | SLC18A3 | Q16572 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26981190 | 0.75 | SMN1; SMN2 (0.58) | CA12CA1CA2CA7CA9 | |
| SCHEMBL30009166 | 0.74 | SIGLEC9 (0.42) | SIGLEC9KMT2ARAB9ALMNAALDH1A1 | |
| SCHEMBL7094585 | 0.71 | SIGLEC9 (0.56) | CA12CA1CA2CA7CA9 | |
| SCHEMBL7094543 | 0.70 | SIGLEC9 (0.55) | CA12CA1CA2CA7CA9 | |
| SCHEMBL324878 | 0.69 | ALDH1A1 (0.63) | CA12CA1CA2CA7CA9 | |
| SCHEMBL30009884 | 0.69 | HPGDS (0.41) | CA12CA1CA2CA7CA9 | |
| SCHEMBL504856 | 0.68 | TFPI2 (0.30) | — | |
| SCHEMBL6931036 | 0.68 | CHRNB2 (0.38) | ALDH1A1 | |
| SCHEMBL30009423 | 0.68 | HTT (0.51) | JAK1KMT2ALMNAALDH1A1MEN1 | |
| SCHEMBL3764385 | 0.67 | CA12 (0.60) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11524968-B2 | Heterocyclic compound as a protein kinase inhibitor | HK INNO.N CORPORATION (KR) | 2022-12-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11524968-B2 | Heterocyclic compound as a protein kinase inhibitor | MAP3K20, MAP3K15, MAP3K1 | CA12 3378/4885CA1 1951/4885CA2 1173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.